Written by Maria S BONINO

NEWSFLASH!

Exciting News On The Covid-19, And FIP Fields

REMDESIVIR obtained full FDA approval

Happy Friday to all our members! It is with great pleasure that we are sharing exciting news released by media outlets worldwide.

Yesterday, it was announced that the Federal Drug Administration (FDA) approved the first drug to treat Covid-19: Remdesivir, an antiviral medicine given to hospitalized patients through an IV. The drug, which California based Gilead Sciences Inc. is calling Veklury, had been authorized for use on an emergency basis since Spring, and now becomes the first drug to win full FDA approval for treating Covid-19.

It is worthwhile to note that earlier this year Gilead Sciences entered into voluntary non-exclusive licensing agreements with generic pharmaceutical companies based in India, Pakistan and Egypt to manufacture and market Remdesivir in 127 countries. Full details and list of countries where this agreement permits distribution is available at: https://www.gilead.com/purpose/advancing-global-health/covid-19/voluntary-licensing-agreements-for-remdesivir?fbclid=IwAR2TnQ8qJKdE5Z9MHoBRPK6wnS-V4qwTY8ShrXcb83o8BCzPfkaPBGjX5qU (Including in South Africa under licence to Cipla)

Remdesivir (GS-5734TM) is a broad-spectrum small molecule antiviral drug that has demonstrated activity against RNA viruses (RNA viruses informational post released on 14 October). The drug was originally developed to treat Ebola virus infection. Remdesivir is a prodrug of the parent adenosine analog (GS-441524TM). It is common knowledge within the FIP community that GS-441524 has displayed antiviral activity against the feline infectious peritonitis causal pathogen. In lay terms, GS-441524 is one of a group of antiviral drugs which block the virus’ ability to make copies of its generic material, essential for its spread and survival.

Based on results for GS-441524, Remdesivir should also be effective against FIP, but to date has not been tested in cats for safety or efficacy. In time, and with additional research, it is extremely likely that rather than use unregulated, untested GS-441524, pet parents and veterinarians caring for cats with FIP could use Remdesivir.

Cats (and dogs) share many diseases and biological processes with people, and where a licensed drug in animals does not exist, veterinarians can prescribe the human drug to an animal with care. In other words, off-label use of pharmaceuticals licensed for treatment of human diseases is common in veterinary medicine, especially in companion animals.

With Remdisivir obtaining full FDA approval, the days of the Chinese sourced illegal GS 441 524 black market will soon come to an end, and with its demise so the lack of safety, price gouging, emotional blackmail amongst many other things.

As you all are aware the EndFIP® brand does NOT support nor does it promote the use of unregulated substances, nor entice desperate individuals to acquire them. Furthermore, we never allow our brand to be used as a platform to discuss or promote the distribution of uncontrolled, unregulated substances. We made it very clear that we are not against GS and that we welcome a legal form of GS 441524. The headlines released yesterday are very welcome news indeed!

Those interested in reading the official press releases – can obtain full details here:

To ensure you receive regular articles and educational awareness posts on feline coronavirus and FIP, please join

www.facebook.com/groups/EndFIP/

or access www.endfip.com

NEWSFLASH!

Exciting News On The Covid-19, And FIP Fields

REMDESIVIR obtained full FDA approval

Happy Friday to all our members! It is with great pleasure that we are sharing exciting news released by media outlets worldwide.

Yesterday, it was announced that the Federal Drug Administration (FDA) approved the first drug to treat Covid-19: Remdesivir, an antiviral medicine given to hospitalized patients through an IV. The drug, which California based Gilead Sciences Inc. is calling Veklury, had been authorized for use on an emergency basis since Spring, and now becomes the first drug to win full FDA approval for treating Covid-19.

It is worthwhile to note that earlier this year Gilead Sciences entered into voluntary non-exclusive licensing agreements with generic pharmaceutical companies based in India, Pakistan and Egypt to manufacture and market Remdesivir in 127 countries. Full details and list of countries where this agreement permits distribution is available at: https://www.gilead.com/purpose/advancing-global-health/covid-19/voluntary-licensing-agreements-for-remdesivir?fbclid=IwAR2TnQ8qJKdE5Z9MHoBRPK6wnS-V4qwTY8ShrXcb83o8BCzPfkaPBGjX5qU (Including in South Africa under licence to Cipla)

Remdesivir (GS-5734TM) is a broad-spectrum small molecule antiviral drug that has demonstrated activity against RNA viruses (RNA viruses informational post released on 14 October). The drug was originally developed to treat Ebola virus infection. Remdesivir is a prodrug of the parent adenosine analog (GS-441524TM). It is common knowledge within the FIP community that GS-441524 has displayed antiviral activity against the feline infectious peritonitis causal pathogen. In lay terms, GS-441524 is one of a group of antiviral drugs which block the virus’ ability to make copies of its generic material, essential for its spread and survival.

Based on results for GS-441524, Remdesivir should also be effective against FIP, but to date has not been tested in cats for safety or efficacy. In time, and with additional research, it is extremely likely that rather than use unregulated, untested GS-441524, pet parents and veterinarians caring for cats with FIP could use Remdesivir.

Cats (and dogs) share many diseases and biological processes with people, and where a licensed drug in animals does not exist, veterinarians can prescribe the human drug to an animal with care. In other words, off-label use of pharmaceuticals licensed for treatment of human diseases is common in veterinary medicine, especially in companion animals.

With Remdisivir obtaining full FDA approval, the days of the Chinese sourced illegal GS 441 524 black market will soon come to an end, and with its demise so the lack of safety, price gouging, emotional blackmail amongst many other things.

As you all are aware the EndFIP® brand does NOT support nor does it promote the use of unregulated substances, nor entice desperate individuals to acquire them. Furthermore, we never allow our brand to be used as a platform to discuss or promote the distribution of uncontrolled, unregulated substances. We made it very clear that we are not against GS and that we welcome a legal form of GS 441524. The headlines released yesterday are very welcome news indeed!

Those interested in reading the official press releases – can obtain full details here:

To ensure you receive regular articles and educational awareness posts on feline coronavirus and FIP, please join

www.facebook.com/groups/EndFIP/

or access www.endfip.com

Paylaşmak önemsemektir!

Share

Bir cevap yazın

E-posta hesabınız yayımlanmayacak.

Copy Protected by Chetan's WP-Copyprotect.